ISO TREATMENT Sample Clauses

ISO TREATMENT. It is intended that the Option shall qualify as an "incentive stock option" as described in Section 422 of the Internal Revenue Code of 1986, as amended.
Sample 1Sample 2Sample 3See All (41)
AutoNDA by SimpleDocs
ISO TREATMENT. It is intended that the Option shall qualify as an "incentive share option" as described in Section 422 of the Internal Revenue Code of 1986, as amended within the limitations outlined in Section 2.5 of the 2000 Plan.
Sample 1Sample 2Sample 3See All (14)
ISO TREATMENT. It is not intended that the Option shall qualify as an "incentive stock option" as described in section 422 of the Internal Revenue Code of 1986, as amended.
Sample 1Sample 2Sample 3See All (7)
ISO TREATMENT. If designated in the Notice of Grant as Incentive Stock Options, the Options granted pursuant to this Award are intended to qualify for favorable tax treatment as Incentive Stock Options (also known as “ISOs”) as defined in Section 422 of the Internal Revenue Code. Nevertheless, to the extent that the Fair Market Value of shares of Common Stock with respect to which ISOs are exercisable for the first time during any calendar year exceeds $100,000, this Option shall be treated as a Nonstatutory Stock Option. Furthermore, neither the Company nor any other person or entity guarantees, warrants or otherwise represents that this Award will produce any favorable or desired tax or other result. If Optionholder sells or otherwise disposes of any of the shares of Common Stock acquired pursuant to an ISO on or before the later of (1) the date two (2) years after the Date of Grant as set forth in Section I, and (2) the date one (1) year after the date of exercise, Optionholder must immediately notify the Company in writing of such disposition.
Sample 1
ISO TREATMENT. The Options shall, to the fullest extent permitted under applicable tax laws, be structured to qualify as "incentive stock options" with the meaning of Section 422(b) of the Internal Revenue Code.
Sample 1
ISO TREATMENT. The Options are intended to satisfy the requirements of Section 422 of the Code relating to the issuance of “incentive stock options” (“ISOs”). In addition to the other terms and conditions relating to the Options as described elsewhere in this Agreement, the following applies with respect the Options: (i) the Administrator has determined that as of the date hereof, the fair market value of one share of Common Stock of the Company does not exceed the Exercise Price; (ii) Optionee shall not be granted Options under this Agreement during any twelve-month period covering more than 1,000,000 shares; and (iii) this Agreement, and the issuance of the Options hereunder, has been approved by the holders of a majority of the Company’s outstanding shares of stock.
Sample 1
ISO TREATMENT. The Option is intended to qualify as an Incentive Stock Option pursuant to Section 422 of the Internal Revenue Code of 1986, as amended. Provided, however, that if the aggregate fair market value (determined on the Date of Grant) of the Incentive Stock Options (under this and any other plan of the Company and its Subsidiaries or parent) which become exercisable by you for the first time during any calendar year exceeds $100,000, such Options shall be treated as Non-statutory Stock Options.
Sample 1
AutoNDA by SimpleDocs

Related to ISO TREATMENT

  • Equal Treatment No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors and assigns.

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • Confidential Treatment The parties hereto understand that any information or recommendation supplied by the Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Investment Manager, the Company or such persons the Investment Manager may designate in connection with the Fund. The parties also understand that any information supplied to the Sub-Adviser in connection with the performance of its obligations hereunder, particularly, but not limited to, any list of securities which may not be bought or sold for the Fund, is to be regarded as confidential and for use only by the Sub-Adviser in connection with its obligation to provide investment advice and other services to the Fund.

  • Consistent Treatment Unless and until there has been a Final Determination to the contrary, each Party agrees not to take any position on any Tax Return, in connection with any Tax Contest or otherwise that is inconsistent with (i) the treatment of payments between the Parent Group and the SpinCo Group as set forth in Section 5.4, (ii) the Tax Materials or (iii) the Intended Tax Treatment.

  • REIT Treatment The Company will use its best efforts to meet the requirements to qualify as a “real estate investment trust” under the Code for any taxable years that include any portion of the term of this Agreement.

  • Corporate Treatment The Board shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Board determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company’s status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Board may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a “C” corporation pursuant to the Code (a “Change in Tax Classification”), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the Service, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Board shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company no longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall no longer apply.

  • CONFIDENTIAL TREATMENT REQUESTED Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission.

  • Equal Treatment of Purchasers No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

  • Treatment of Options Immediately prior to the Effective Time, each option to purchase Shares (each, a “Company Option”) under any stock option or other equity or equity-based plan of the Company, including the 2007 Equity and Incentive Plan, as amended and restated effective as of June 11, 2013 (the “Company Equity Plans”), that is unexpired and unexercised and vested immediately prior to the Effective Time (a “Vested Company Option”) (or portion thereof), shall be cancelled and, in exchange therefor, each former holder of any such cancelled Vested Company Option shall be entitled to receive, in consideration of the cancellation of such Vested Company Option and in settlement therefor, a payment in cash (subject to any applicable withholding or other Taxes required by applicable Law) of an amount equal to the product of (i) the total number of Shares subject to such Vested Company Option immediately prior to such cancellation and (ii) the excess, if any, of the Merger Consideration over the exercise price per Share subject to such Vested Company Option immediately prior to such cancellation (such amounts payable hereunder being referred to as the “Option Payments”). No holder of a Vested Company Option that, as of immediately prior to such cancellation, has an exercise price per Share that is equal to or greater than the Merger Consideration shall be entitled to any payment with respect to such cancelled Vested Company Option. From and after the Effective Time, each Vested Company Option shall no longer be exercisable by the former holder thereof, but shall only entitle such holder to the payment of the Option Payment, if any. On or as soon as practicable following the Closing, but in any event no later than 15 days following the Closing, the Surviving Corporation shall make, by a payroll payment through the Company’s or Merger Sub’s payroll provider and subject to withholding, if any, as described in Section 2.5 to each holder of Vested Company Options, such holder’s Option Payment.

Time is Money Join Law Insider Premium to draft better contracts faster.